Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Immunotherapy
•
Renal Cell Carcinoma
•
NCI-CCC Tumor Board Question
•
Duke
•
NCI-CCC GU Tumor Board Question
In a patient with metastatic RCC who discontinued nivolumab after a prolonged response to ipilimumab/nivolumab, would you consider re-starting nivolumab at disease progression?
Related Questions
How do you manage recurrent asymptomatic transaminitis from VEGF TKI in a patient renal cell carcinoma who needs drug to control disease?
Would you offer adjuvant immunotherapy (pembrolizumab) for chromophobe RCC with R1 resection?
How do you manage anemia associated with belzutifan therapy?
What is your preferred regimen for a patient with clear cell RCC, progression after an IO+IO regimen, with a chronic non-healing wound?
How are you utilizing subcutaneous Nivolumab in genitourinary cancers?
How do you manage hypoxia induced by belzutifan?
What are your top takeaways in GU Cancers from ESMO 2024?
Do you recommend any alternative schedule for cabozantinib to make treatment compliance easier for patients with metastatic renal cell carcinoma?
What are your top takeaways from ASCO GU 2025?
How often do you monitor for pancreatitis (check lipase/amylase) while on Axitinib?
